CN109512809A - Fucoxanthin is preventing or is treating pyemia and preparing the application of medication for treating pyemia - Google Patents
Fucoxanthin is preventing or is treating pyemia and preparing the application of medication for treating pyemia Download PDFInfo
- Publication number
- CN109512809A CN109512809A CN201811510883.5A CN201811510883A CN109512809A CN 109512809 A CN109512809 A CN 109512809A CN 201811510883 A CN201811510883 A CN 201811510883A CN 109512809 A CN109512809 A CN 109512809A
- Authority
- CN
- China
- Prior art keywords
- fucoxanthin
- pyemia
- lps
- group
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to fucoxanthin to prevent or treat pyemia and prepare the application of medication for treating pyemia.Our experiments show that fucoxanthin has significant protective effect to pyemia.Experimental study shows that the survival rate of 120 h for the pyemia mouse that fucoxanthin induces LPS is improved by zero to 40%(P < 0.05 in Mice Body), and inhibit the expression of inflammatory factor in serum to some extent, In vitro cell experiment research discovery fucoxanthin significantly inhibits the phosphorylation level of the NF- κ B signal access by LPS induction, reduce the nuclear translocation of Nuclear Factor kappa B, inhibit inflammatory factor expression, to up to prevention or treat pyemic effect.
Description
Technical field
The present invention relates to fucoxanthin to prevent or treat pyemia and prepare the application of medication for treating pyemia, pharmaceutical chemistry
Technical field.
Background technique
As the significant problem for influencing public health, the research of pyemia (sepsis) has become modern Severe acute disease medicine
One of very active Disciplinary Frontiers, every year there are about 18,000,000 sepsis patients, the death rate is suffered from 28-50% in the whole world
Sick rate increases to 6% by 1.5%, and increase situation is obvious, and patient more than half of them moves in intensive care unit (ICU),
In every 3 institutes in Died Patients, just having 1 is sepsis patient, more 5 times of other patient's expenses of medical expense ratio ICU.2016
2 months years severe medical association, the U.S. (SCCM) combines the newest pyemia definition of publication and diagnosis with European severe medical association (ESICM)
Standard (3.0 version of pyemia), it is believed that pyemia is the organ dysfunction that body lacked of proper care and caused threat to life to the reaction of infection
Obstacle.This definition is more concerned about the complicated pathologic-physiological reaction occurred when body reply infection, emphasizes " the organ function of threat to life
Energy obstacle ".Newest pyemia defines and the more accurately diagnosing and treating pyemia that is established as of diagnostic criteria is laid a good foundation, and is
Epidemiological study from now on and clinical test provide better reference standard.The focus and difficult point for the treatment of of sepsis drug research
It is that can drug effectively improve patient survival.Pyemic pathogenesis is extremely complex, also much fails to illustrate so far,
In particular with quitting listing for recombinant activated human protein c (rhAPC), clearly effective medicinal application facing in the disease there is no at present
Bed treatment.
Current established pyemia animal model mainly has 3 classes: toxaemia model, bacterial infection model and host's barrier
Damage model.Toxaemia model be in sepsis model earliest be also most common animal model, inject toxin such as lipopolysaccharides
(Lipopolysaccharides, LPS) constructs inflammatory model, induces the generation of the inflammatory factors such as TNF-α, IL-1 β, IL-6, draws
Send out systemic inflammatory responses similar with the mankind.
Fucoxanthin (Fucoxanthin, FX) is also known as black canthaxanthin, is a kind of fat-soluble orange pigment, is class Hu trailing plants
One of the most abundant compound in fore-telling, accounts for 10% or more of carotenoid total output in nature, especially in ocean ring
It is widely present in border.The industrial fucoxanthin price that purity is 10% on current domestic market is 3000 yuan of per kilogram or so, rock
The phycoxanthine standard items market price is every gram about 150,000 yuan of RMB.Fucoxanthin is from seas such as entoilage Trentepohlia, kelps earliest
It is separated in foreign brown seaweed.Fucoxanthin in microalgae such as diatom, chrysophyceae and is determined in addition to being present in the tangleweeds such as brown alga
It is also widely present in whip algae, because fucoxanthin content is higher in algae, shows characteristic brown color, fucoxanthin is in photosystem
Catch in light complex and play an important role.
There are four types of optical isomers for fucoxanthin, and molecular structure is unique, as shown in Figure 1, containing 1 polyenoid hydrocarbon skeleton, belong to
In allene type carotenoid, contain uncommon allene key and 5,6- monocycle oxygroup, in addition 9- conjugated double bond, carbonyl and hydroxyl
The functional groups such as base.These features impart the unique physiological activity of fucoxanthin and unstability.Fucoxanthin is extremely unstable
Fixed, chance light, heat, soda acid etc. are easily oxidized and isomerization, to degrade.
Fucoxanthin is with anti-oxidant, antitumor, anticancer, anti-angiogenesis, anti-malarial, anti-acne, weight-reducing and eyesight
The different physiological roles such as protection, are widely applied to the industries such as aquatic products livestock culture, cosmetics, healthy food and pharmacy.It is reported that
Fucoxanthin has certain effect in diseases such as prevention breast cancer, prostate cancer, colon cancer, lung cancer and cutaneum carcinomas.It is taken the photograph in diet
Most of fucoxanthin entered can be converted to fucoxanthol, the latter may inhibitory effect to cancer cell it is more yellow than rock algae in vivo
It is plain more effective.Research is found: fucoxanthin and fucoxanthol can induce different types of cancer cell, make their growth by
The antitumaous effect of inhibition or even apoptosis, fucoxanthin and fucoxanthol is by inhibiting cell Proliferation, inducing cell apoptosis, carefully
The mechanisms mediate of born of the same parents' Cycle Arrest and anti-angiogenesis, but protective effect to pyemia mouse and Mechanism Study are not yet appeared in the newspapers
Road.Based on this, the present inventor has invented fucoxanthin suppression on the basis of closely tracking pyemia mechanism New research progress
Pyemic occurrence and development are made, for preparation prevention or treat pyemic drug.Summary of the invention
In order to solve the above problem present in the prior art, the present invention provides fucoxanthin and is preventing or treating pyemia
And prepare the application of medication for treating pyemia, and in particular to fucoxanthin is by inhibiting the phosphorus by the LPS NF- κ B signal access induced
Acidification is horizontal, reduces the nuclear translocation of Nuclear Factor kappa B, inhibits inflammatory factor expression, and then improve survival rate, to reach
Prevention or treatment pyemia.
Technical scheme is as follows:
Fucoxanthin is preventing or is treating the application in pyemia.
Preferably, fucoxanthin is inhibited inflammatory factor expression and then is reached by the nuclear translocation of reduction Nuclear Factor kappa B
To prevention or treatment pyemia.
The invention also includes a kind of fucoxanthin to prevent or treat the application in pyemic drug, fucoxanthin in preparation
According to dosage needs, pharmaceutically acceptable carrier or auxiliary material is added, with injection, tablet, freeze-dried powder, capsule, film
Sheet form is coated to exist.The auxiliary material can for starch, pregelatinized starch, dextrin, sucrose, lactose, mannitol, microcrystalline cellulose,
Pregelatinized starch, dextrin, sucrose, lactose, mannitol, microcrystalline cellulose etc..
Preferably, the fucoxanthin injection dosage range is 0.1mg/kg-10mg/kg.
The structural formula of the fucoxanthin are as follows:
Compared with prior art, beneficial effects of the present invention are as follows:
1, fucoxanthin of the invention reduces core by inhibiting the phosphorylation level by the LPS NF- κ B signal access induced
The nuclear translocation of transcription factor NF-KB inhibits inflammatory factor expression, and then improves survival rate, to reach prevention or treatment septicopyemia
Disease.
2, the present invention shows that fucoxanthin makes the 120h's of the pyemia mouse of LPS induction by experimental study in Mice Body
Survival rate is improved by zero to 40% (P < 0.05), and inhibits the expression of inflammatory factor in serum to some extent, and cell in vitro is real
The phosphorylation level that research discovery fucoxanthin significantly inhibits the NF- κ B signal access by LPS induction is tested, nuclear factor is reduced
The nuclear translocation of NF- κ B inhibits inflammatory factor expression, to up to prevention or treat pyemic effect.
Detailed description of the invention
Fig. 1 is the structural schematic diagram of fucoxanthin and its isomer of the present invention；
Fig. 2 is influence of the fucoxanthin of various dose of the present invention to the LPS septicopyemia disease mouse model survival rate induced
Schematic diagram；
Fig. 3 is that the IL-1 β in the septicopyemia disease mouse model serum that the fucoxanthin of various dose of the present invention induces LPS contains
Measure the schematic diagram of the influence of variation；
Fig. 4 is that the IL-6 in the septicopyemia disease mouse model serum that the fucoxanthin of various dose of the present invention induces LPS contains
Measure the schematic diagram of the influence of variation；
Fig. 5 is that the TNF-α in the septicopyemia disease mouse model serum that the fucoxanthin of various dose of the present invention induces LPS contains
Measure the schematic diagram of the influence of variation；
Fig. 6 is signal of the fucoxanthin of the present invention to the influence of cellular inflammation factor IL-1 β expression after LPS stimulation
Figure；
Fig. 7 is schematic diagram of the fucoxanthin of the present invention to the influence of cellular inflammation factor IL-6 expression after LPS stimulation；
Fig. 8 is the influence schematic diagram that fucoxanthin of the present invention expresses LPS stimulation RAW264.7 cell I κ B α and NF- κ B；
Fig. 9 is influence schematic diagram of the fucoxanthin of the present invention to pNF- κ B and NF- κ B ratio；
Figure 10 is influence schematic diagram of the fucoxanthin of the present invention to pI κ B α and I κ B α ratio；
Figure 11 is that fucoxanthin of the present invention stimulates THP1-Lucia to LPSTMShadow of the NF- κ B cell to NF- κ B Transcription inhibition
Ring schematic diagram.
Specific embodiment
It is next combined with specific embodiments below that the present invention will be described in detail.
Embodiment one
Verifying fucoxanthin influences mouse survival rate in LPS induction septicopyemia disease mouse model
Test method is as follows:
90 C57BL/6 mouse are randomly divided into 9 groups, respectively blank control group, LPS model group, fucoxanthin at random
(0.1mg/kg) group, fucoxanthin (1.0mg/kg) group, fucoxanthin (10mg/kg) group, fucoxanthin (0.1mg/kg)+LPS
Group, fucoxanthin (1.0mg/kg)+LPS group, fucoxanthin (10.0mg/kg)+LPS group and positive controls ulinastatin
Ulinastatin(104U/kg), every group 10；Wherein LPS model group intraperitoneal injection LPS (40.0mg/kg), fucoxanthin+
LPS group is divided into fucoxanthin (0.1mg/kg)+LPS group, fucoxanthin (1.0mg/kg)+LPS group and fucoxanthin (10.0mg/
Kg)+LPS group, fucoxanthin 0.1mg/kg, 1.0mg/kg and 10.0mg/kg is injected intraperitoneally in 30min before injecting LPS, empty
The physiological saline of white group of intraperitoneal injection equivalent.The equal pre-operative anxiety 12h of all mouse, free water.Every 12h observation note in 120h
The Survival for recording mouse carries out statistical analysis using survival rate of the Kaplan-Meier survival analysis method to each group mouse
(log-rank inspection).
Test result is as follows:
Fucoxanthin influences the septicopyemia disease mouse model survival rate that LPS is induced
As shown in Fig. 2, identical as blank control group, 0.1mg/kg, 1.0mg/kg that fucoxanthin drug is individually injected and
The mouse survival rate of 3 various dose groups of 10.0mg/kg is 100%, illustrates fucoxanthin drug itself to mouse survival rate
Not apparent toxicity；At the same time, the mouse survival rate of fucoxanthin medicine group is higher than LPS model group, wherein with 1mg/
The dosage group of kg is the most significant (P < 0.01), and mouse survival rate has been increased to 40% by 0%, and the dosage group of 10mg/kg is survived
Rate is only 20%, and experimental result illustrates that fucoxanthin can significantly improve the inflammation mouse survival rate of LPS induction, but fucoxanthin
Drug dose and the inflammation mouse survival rate that LPS is induced be not directly proportional, after selecting the fucoxanthin of 1.0mg/kg dosage to be used for
Continuous experimental study.
Meanwhile being found in mouse state observation in an experiment, the mouse in blank control group is in good condition, active good
Dynamic, fur gloss is fine and closely woven, eupnea, stool forming；LPS model group mouse breathes after LPS half an hour is injected intraperitoneally
Hurriedly, it rolls up and moves less, phenomena such as hair is wet, and food refusal is just dilute, and eye discharge increases, over time, the state of an illness adds
It is heavy, start to occur after 12h dead；The state of fucoxanthin treatment group mouse takes an evident turn for the better compared with LPS model group.
Embodiment two
The inhibition of inflammatory factor release in the septicopyemia disease mouse model serum that ELISA method analysis fucoxanthin induces LPS
Effect
Experimental method is as follows:
12h eye socket is taken a blood sample after modeling administration, separates serum, and according to the operating procedure of ELISA kit specification, detection is outer
Inflammatory factor IL-1 β in the serum of all blood, IL-6, TNF-α expression.Concrete operations are as described below:
Make its balance to room temperature 1. required kit is placed at room temperature for half an hour or more before experiment；Experiment is divided into
Totally 4 groups of blank control, negative control, positive control, experimental group etc., every group of experiment in triplicate, and carries out detailed record.
2. taking out elisa plate item from having balanced into the kit of room temperature, (what is do not used should be returned to 4 DEG C of ice immediately
Case),
3. standard items are diluted by dilution method step by step, the standard dilution that dilution uses kit to be furnished with, every
50 μ L Sample dilutions and 50 μ L samples to be detected are respectively added in a lath, then add 50 μ L biotin antibody working solutions
(1:100 dilution, retarder thinner is Sample dilution, using being prepared in preceding 30min, only good the day interior use) and, will with sealing strip
Lath sealing, is incubated at room temperature 2h, preferably uses micro oscillator.
It, during which can be into 4. manually board-washing 5 times (each time should take the cleaning solution in its reacting hole after board-washing)
(1:100 dilution, retarder thinner is Sample dilution, using preparing in preceding 30min, is only limited for the preparation of row enzyme conjugates working solution
Used when in a few days), it is placed at room temperature for, it should be noted that be kept in dark place；100 hole μ L/ of enzyme conjugates working solution is added, with sealing strip by lath
Sealing；It is incubated at room temperature 1h, preferably uses micro oscillator.
5. manually second board-washing 5 times (each time should take the cleaning solution in its reacting hole after board-washing)；So
100 μ L chromogenic substrates (including blank well) are added in every hole afterwards, and room temperature, which is protected from light, is incubated for 15min.
6. 100 μ L terminate liquids (including blank well) are added in every hole, be gently mixed it is even after measured immediately in 10min its
OD value at 450nm finally carries out Data Analysis Services.
7. being mapped with Graphpad prism5 software, indicated using mean (average value)+S.E.M. (reference substance), by
The significance of difference between Graphpad prism5 software analysis data, using one-way analysis of variance method.
Test result is as follows:
Influence of the ELISA method detection fucoxanthin to the LPS septicopyemia disease mouse model serum levels of inflammatory cytokines expression induced
(the "+" expression in figure is added to this kind of substance, and "-" expression is not added with this kind of substance, similarly hereinafter) known to analysis chart 3,
Compared with blank control group, the IL-1 β content in LPS model group mice serum is significantly raised (P < 0.001), with rock algae
The content of the increase of flavine injection concentration, IL-1 β is constantly reduced, wherein fucoxanthin (10.0mg/kg) treatment group mice serum
In IL-1 β content but compare LPS group and significantly reduce (P < 0.01).
For analysis chart 4 it is found that compared with blank control group, the IL-6 content in LPS model group mice serum is significantly raised
(P < 0.001), with the increase of fucoxanthin injection concentration, the content of IL-6 is constantly reduced, wherein the low middle high agent of fucoxanthin
IL-1 β content in amount (0.1mg/kg, 1.0mg/kg, 10.0mg/kg) treatment group mice serum is compared LPS group and is significantly reduced
(P < 0.001).
For analysis chart 5 it is found that compared with blank control group, the TNF-α content in LPS model group mice serum is significantly raised
(P < 0.001), wherein the TNF-α content in fucoxanthin (1.0mg/kg) treatment group mice serum compares LPS group inhibitory effect
Most preferably (P < 0.01).
Embodiment three
QPCR analyzes the influence that fucoxanthin expresses cellular inflammation factor level after LPS stimulation
Experimental method is as follows:
Respectively at prepared RAW264.7 cell suspension, cell concentration 1 × 10 are added in 6 orifice plates6/ hole, every hole 1mL,
37 DEG C are subsequently placed in, 5%CO2Incubator culture for 24 hours；Different drug-treateds, 4 groups of experiment point: blank control is added in every hole
Group, LPS group (1mg/L), fucoxanthin group (10.0nmol/L), LPS+ fucoxanthin group: fucoxanthin is first added
After (10.0nmol/L) cultivates 6h, after adding lipopolysaccharides (1.0mg/L) culture 3 hours；Collect group of cells respectively, in 4 DEG C,
3000rpm is centrifuged 10min, takes cell, culture medium supernatant be placed in after packing -80 DEG C it is to be measured.It is extracted using Trizol one-step method thin
Born of the same parents' total serum IgE.MRNA generates cDNA through reverse transcription reaction, and carries out real-time fluorescence quantitative PCR as template；Real time fluorescent quantitative
PCR selects SYBR green method to acquire testing gene and internal reference by ABI Step One plus type fluorescence quantitative PCR instrument
GAPDH expands each circulation fluorescence signal, carries out fluorescent collecting through Applied Biosystems SDS software and data are analyzed.With
The mapping of Graphpad prism5 software, is indicated using mean (average value)+S.E.M. (reference substance), by Graphpad prism5
The significance of difference between software analysis data, using one-way analysis of variance method.
Test result is as follows:
QPCR analyzes the influence that fucoxanthin expresses cellular inflammation factor level after LPS stimulation
It is found that compared with blank control group, the inflammatory factor IL-1 β in LPS group RAW264.7 cell is transcribed to live analysis chart 6
Property significantly raise (P < 0.01)；Fucoxanthin (10.0nmol/L) independent role turns RAW264.7 cellular inflammation factor IL-1 β
Record activity simultaneously has no significant effect (P > 0.05)；Compared with LPS group, fucoxanthin+LPS group can be significantly inhibited to be induced by LPS
The up-regulation of RAW264.7 cellular inflammation factor IL-1 β transcriptional activity acts on (P < 0.05).
It is found that compared with blank control group, the inflammatory factor IL-6 in LPS group RAW264.7 cell is transcribed to live analysis chart 7
Property significantly raise (P < 0.01)；Fucoxanthin (10.0nmol/L) independent role transcribes RAW264.7 cellular inflammation factor IL-6
Activity simultaneously has no significant effect (P > 0.05)；Compared with LPS group, fucoxanthin+LPS group can be significantly inhibited to be induced by LPS
The up-regulation of RAW264.7 cellular inflammation factor IL-6 transcriptional activity acts on (P < 0.05).
Example IV
The influence that fucoxanthin expresses LPS stimulation RAW264.7 cell I κ B α and NF- κ B
Experimental method is as follows:
Respectively at prepared RAW264.7 cell suspension, cell concentration 1 × 10 are added in 6 orifice plates6/ hole, every hole 1mL,
37 DEG C are subsequently placed in, 5%CO2Incubator culture for 24 hours；Different drug-treateds, 4 groups of experiment point: blank control is added in every hole
Group, LPS group (1mg/L), fucoxanthin group (10.0nmol/L), LPS+ fucoxanthin group: first it is separately added into fucoxanthin
(10.0nmol/L) cultivate 1h, 3h and 6h after, then with LPS (1.0mg/L) stimulation 10min；Collect group of cells respectively, in 4 DEG C,
3000rpm be centrifuged 10min, remove supernatant after extract proteins, albumen be placed in after packing -80 DEG C it is to be measured.Pass through Western blot
Method detects the variation of GAP-associated protein GAP in NF- κ B signal access.It is mapped with Graphpad prism5 software, it is (average using mean
Value)+S.E.M. (reference substance) expression, by the significance of difference between Graphpad prism5 software analysis data, using list
Analysis of variance method.
Test result is as follows:
The influence that fucoxanthin expresses LPS stimulation RAW264.7 cell I κ B α and NF- κ B
Analysis chart 8 to Figure 10 it is found that after LPS is stimulated, the phosphorylation degree of I κ B α and NF- κ B significantly improve (P <
0.001), this shows that LPS can promote Inflammatory Pathway to express, and compared with LPS group, fucoxanthin (10.0nmol/L) is incubated for 3h
Afterwards, then the LPS through 1.0mg/L stimulates 10min, then can significantly lower I κ B α and NF- κ B phosphorylation level, and with LPS group and
HupA group is more statistically significant (P < 0.01).
Embodiment five
Fucoxanthin stimulates THP1-Lucia to LPSTMInfluence of the NF- κ B cell to NF- κ B Transcription inhibition
Experimental method is as follows:
Respectively at prepared THP1-LuciaTMNF- κ B cell suspension, cell concentration 1 × 10 are added in 96 orifice plates5/
Hole, every hole 0.2mL, is subsequently placed in 37 DEG C, 5%CO2Incubator culture for 24 hours；Every hole be added the fucoxanthin of various concentration with
LPS (1.0mg/ml) collects supernatant after co-culturing 16 hours.Take 10 microlitres of culture medium supernatant that 96 holes of opaque board bottom are added
Plate adds after 40 microlitres of developing solution and surveys fluorescence intensity with microplate reader, and fluorescence intensity represents the activity of NF- kB protein.
Test result is as follows:
Analysis chart 11 is it is found that the fucoxanthin of low concentration (30-300nM) can not inhibit by the LPS NF- kB protein induced
Activation；The fucoxanthin (1-20 μM) of high concentration shows a dose-dependant for the activation of the NF- kB protein induced by LPS
Inhibitory effect, wherein EC50(half-maximal effect concentration) is 3.78 μM.
The above description is only an embodiment of the present invention, is not intended to limit the scope of the invention, all to utilize this hair
Equivalent structure or equivalent flow shift made by bright description is applied directly or indirectly in other relevant technology necks
Domain is included within the scope of the present invention.
Claims (6)
1. fucoxanthin is preventing or is treating the application in pyemia.
2. fucoxanthin as described in claim 1 is preventing or is treating the application in pyemia, it is characterised in that: fucoxanthin
By reducing the nuclear translocation of Nuclear Factor kappa B, inhibiting inflammatory factor expression and then reaching prevention or treatment pyemia.
3. fucoxanthin as claimed in claim 1 or 2 is preventing or is treating the application in pyemia, it is characterised in that: described
The structural formula of fucoxanthin are as follows:
4. fucoxanthin prevents or treats the application in pyemic drug in preparation, it is characterised in that: fucoxanthin is according to agent
Amount needs, and pharmaceutically acceptable carrier or auxiliary material is added, with injection, tablet, freeze-dried powder, capsule, thin membrane coated tablet
Form exists.
5. fucoxanthin as claimed in claim 4 prevents or treat the application in pyemic drug in preparation, feature exists
In: the fucoxanthin injection dosage range is 0.1mg/kg-10mg/kg.
6. fucoxanthin as described in claim 4 or 5 prevents or treats the application in pyemic drug, feature in preparation
It is: the structural formula of the fucoxanthin are as follows:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811510883.5A CN109512809A (en) | 2018-12-11 | 2018-12-11 | Fucoxanthin is preventing or is treating pyemia and preparing the application of medication for treating pyemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811510883.5A CN109512809A (en) | 2018-12-11 | 2018-12-11 | Fucoxanthin is preventing or is treating pyemia and preparing the application of medication for treating pyemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109512809A true CN109512809A (en) | 2019-03-26 |
Family
ID=65795891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811510883.5A Pending CN109512809A (en) | 2018-12-11 | 2018-12-11 | Fucoxanthin is preventing or is treating pyemia and preparing the application of medication for treating pyemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109512809A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112022888A (en) * | 2020-09-25 | 2020-12-04 | 温州大学 | Traditional Chinese medicine composition with anti-inflammatory effect, application and anti-inflammatory pharmaceutical preparation |
| CN113413399A (en) * | 2021-06-16 | 2021-09-21 | 福建师范大学 | Application of tea fungus fermentation liquor in preparation of medicine for preventing or treating sepsis induced by LPS (low-pressure lipoprotein lipase) |
| CN115919832A (en) * | 2022-11-07 | 2023-04-07 | 福建师范大学 | Application of fucoxanthin in preparation of medicine for treating or preventing sepsis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150182487A1 (en) * | 2012-09-17 | 2015-07-02 | Jeju National University Industry Academic Cooperation Foundation | Composition for preventing and treating inflammatory diseases and immune diseases, containing apo-9`-fucoxanthinone as active ingredient |
| JP2018131429A (en) * | 2017-02-14 | 2018-08-23 | 拓己 佐藤 | Use of organic acid as method to enhance effect of nrf2 activator |
-
2018
- 2018-12-11 CN CN201811510883.5A patent/CN109512809A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150182487A1 (en) * | 2012-09-17 | 2015-07-02 | Jeju National University Industry Academic Cooperation Foundation | Composition for preventing and treating inflammatory diseases and immune diseases, containing apo-9`-fucoxanthinone as active ingredient |
| JP2018131429A (en) * | 2017-02-14 | 2018-08-23 | 拓己 佐藤 | Use of organic acid as method to enhance effect of nrf2 activator |
Non-Patent Citations (4)
| Title |
|---|
| KENJI SHIRATORI等: "Effects of fucoxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo", 《EXPERIMENTAL EYE RESEARCH》 * |
| KIL-NAM KIM等: "Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-κB and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages", 《EUROPEAN JOURNAL OF PHARMACOLOGY》 * |
| REGISTRY: "3351-86-8", 《STN》 * |
| 周庭银等主编: "《血流感染实验诊断与临床诊治》", 31 May 2014, 上海科学技术出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112022888A (en) * | 2020-09-25 | 2020-12-04 | 温州大学 | Traditional Chinese medicine composition with anti-inflammatory effect, application and anti-inflammatory pharmaceutical preparation |
| CN113413399A (en) * | 2021-06-16 | 2021-09-21 | 福建师范大学 | Application of tea fungus fermentation liquor in preparation of medicine for preventing or treating sepsis induced by LPS (low-pressure lipoprotein lipase) |
| CN115919832A (en) * | 2022-11-07 | 2023-04-07 | 福建师范大学 | Application of fucoxanthin in preparation of medicine for treating or preventing sepsis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109512809A (en) | Fucoxanthin is preventing or is treating pyemia and preparing the application of medication for treating pyemia | |
| Ma et al. | Correlation between microbes and colorectal cancer: tumor apoptosis is induced by sitosterols through promoting gut microbiota to produce short-chain fatty acids | |
| CN110402143A (en) | The composition of prevention or treatment Metastatic carcinoma in the ovary, carcinoma of endometrium or breast cancer | |
| TWI484967B (en) | Pharmaceutical composition for assisting anti-cancer drugs | |
| Poirier et al. | Post-surgical interval and lesion location within the limbic thalamus determine extent of retrosplenial cortex immediate-early gene hypoactivity | |
| CN104053655A (en) | Use Of Strigolactones And Strigolactone Analogs For Treating Proliferative Conditions | |
| CN104758292A (en) | A use of PD-0332991 in preparation of drugs preventing and treating drug-resistant tumor | |
| Luo et al. | Comprehensive in silico analysis of the probiotics, and preparation of compound probiotics-Polygonatum sibiricum saponin with hypoglycemic properties | |
| CN103880826B (en) | A kind of isobenzofuran ketonic compound and its preparation method and application | |
| Hseu et al. | Antrodia salmonea suppresses epithelial-mesenchymal transition/metastasis and Warburg effects by inhibiting Twist and HIF-1α expression in Twist-overexpressing head and neck squamous cell carcinoma cells | |
| CN109453164A (en) | A kind of antitumor combination medicine | |
| CN107349190A (en) | The application of ar-turmerone | |
| CN105063196B (en) | Proteasome inhibitor combines the application in cholangiocarcinoma treatment with cell autophagy activator | |
| CN109833321A (en) | It is a kind of to reverse liver cancer cells to the pharmaceutical composition of sorafenib drug resistance | |
| CN110898053A (en) | Application of monascin C in preparation of fat-reducing product | |
| CN102038678A (en) | Application of dihydroartemisinin to preparation of tumor cell autophagy induction medicament | |
| CN107343885B (en) | A kind of AZA resveratrol-chalcone derivative is preparing the application in treating diabetic complications drug | |
| Li et al. | Bibliometric and visual analysis of nocturnal enuresis from 1982 to 2022 | |
| CN109771411A (en) | Dihydroquercetin is used to prepare the purposes in the drug for the treatment of fatty liver | |
| Shu et al. | Multi-omics reveals the attenuation of metabolic cardiomyopathy in mice by alkaloids in extracts from Clausena lansium (Lour.) via the transition of gastrointestinal microbiota to an alternative homeostasis | |
| CN109481424A (en) | Isoliquiritigenin, pharmaceutical composition and its application in treatment diabetic nephropathy | |
| CN109771428A (en) | Celastrol combines application of the erastin in the drug for the treatment of non-small cell lung cancer | |
| CN109745314A (en) | Application of the iron chelating agent Deferasirox (DFX) in the drug for the treatment of cervical carcinoma | |
| CN110448569A (en) | A kind of composition with antidiarrheal efficacy and preparation method thereof and its application | |
| CN109330997A (en) | Purposes of the active constituent perillaldehyde in prevention and treatment oropharynx candidiasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190326 |